If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro™ (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can tirzepatide be used in people with blood disorders such as sickle cell disease or hemolytic anemia?
Tirzepatide has not been studied in people with sickle cell disease or hemolytic anemia.
See important safety information, including boxed warning, in the attached prescribing information.
No information is available on the use of tirzepatide with comorbid sickle cell disease or hemolytic anemia because participants were excluded from clinical studies if they had any blood condition that may interfere with glycated hemoglobin (HbA1c) measurement.
Date of Last Review: May 13, 2022